Center-Authored Papers

Filters: Author is Peterson, Leigh  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Vaccine and Infectious Disease Institute
Ramjee G, Kapiga S, Weiss S, Peterson L, Leburg C, Kelly C, Masse B.  2008.  The value of site preparedness studies for future implementation of phase 2/IIb/III HIV prevention trials: experience from the HPTN 055 study.. Journal of acquired immune deficiency syndromes (1999). 47(1):93-100. Abstract
Sexual Partners
Ramjee G, Kapiga S, Weiss S, Peterson L, Leburg C, Kelly C, Masse B.  2008.  The value of site preparedness studies for future implementation of phase 2/IIb/III HIV prevention trials: experience from the HPTN 055 study.. Journal of acquired immune deficiency syndromes (1999). 47(1):93-100. Abstract
PREGNANCY
Ramjee G, Kapiga S, Weiss S, Peterson L, Leburg C, Kelly C, Masse B.  2008.  The value of site preparedness studies for future implementation of phase 2/IIb/III HIV prevention trials: experience from the HPTN 055 study.. Journal of acquired immune deficiency syndromes (1999). 47(1):93-100. Abstract
Incidence
Ramjee G, Kapiga S, Weiss S, Peterson L, Leburg C, Kelly C, Masse B.  2008.  The value of site preparedness studies for future implementation of phase 2/IIb/III HIV prevention trials: experience from the HPTN 055 study.. Journal of acquired immune deficiency syndromes (1999). 47(1):93-100. Abstract
Humans
Ramjee G, Kapiga S, Weiss S, Peterson L, Leburg C, Kelly C, Masse B.  2008.  The value of site preparedness studies for future implementation of phase 2/IIb/III HIV prevention trials: experience from the HPTN 055 study.. Journal of acquired immune deficiency syndromes (1999). 47(1):93-100. Abstract
HIV Infections
Ramjee G, Kapiga S, Weiss S, Peterson L, Leburg C, Kelly C, Masse B.  2008.  The value of site preparedness studies for future implementation of phase 2/IIb/III HIV prevention trials: experience from the HPTN 055 study.. Journal of acquired immune deficiency syndromes (1999). 47(1):93-100. Abstract
Female
Ramjee G, Kapiga S, Weiss S, Peterson L, Leburg C, Kelly C, Masse B.  2008.  The value of site preparedness studies for future implementation of phase 2/IIb/III HIV prevention trials: experience from the HPTN 055 study.. Journal of acquired immune deficiency syndromes (1999). 47(1):93-100. Abstract
Antiviral Agents
Ramjee G, Kapiga S, Weiss S, Peterson L, Leburg C, Kelly C, Masse B.  2008.  The value of site preparedness studies for future implementation of phase 2/IIb/III HIV prevention trials: experience from the HPTN 055 study.. Journal of acquired immune deficiency syndromes (1999). 47(1):93-100. Abstract
Africa
Ramjee G, Kapiga S, Weiss S, Peterson L, Leburg C, Kelly C, Masse B.  2008.  The value of site preparedness studies for future implementation of phase 2/IIb/III HIV prevention trials: experience from the HPTN 055 study.. Journal of acquired immune deficiency syndromes (1999). 47(1):93-100. Abstract
Adult
Ramjee G, Kapiga S, Weiss S, Peterson L, Leburg C, Kelly C, Masse B.  2008.  The value of site preparedness studies for future implementation of phase 2/IIb/III HIV prevention trials: experience from the HPTN 055 study.. Journal of acquired immune deficiency syndromes (1999). 47(1):93-100. Abstract
Administration, Topical
Ramjee G, Kapiga S, Weiss S, Peterson L, Leburg C, Kelly C, Masse B.  2008.  The value of site preparedness studies for future implementation of phase 2/IIb/III HIV prevention trials: experience from the HPTN 055 study.. Journal of acquired immune deficiency syndromes (1999). 47(1):93-100. Abstract
2008
Ramjee G, Kapiga S, Weiss S, Peterson L, Leburg C, Kelly C, Masse B.  2008.  The value of site preparedness studies for future implementation of phase 2/IIb/III HIV prevention trials: experience from the HPTN 055 study.. Journal of acquired immune deficiency syndromes (1999). 47(1):93-100. Abstract